Journal of AIDS and HIV Treatment

HPV 16/18 E6 oncoprotein has been evaluated as a useful biomarker with prognostic abilities as it can detect pre-cancer and cancerous states of cervical cancer progression. A positive E6 assay indicates a high correlation to the cervical cancerous phenotype, not the potential for cervical cancer, thus high specificity in triaging patients during screening. E6 levels of expression associate directly with the severity of cervical intraepithelial neoplasia (CIN) lesions and the risk of

According to global cancer statistics GLOBOCAN, carcinoma of cervix is ranked as the fourth most common malignancy among women worldwide with an estimation of 570,000 cases and 311,000 deaths in 2018. It is the second most common female malignancy in Lowand- Middle Income Countries (LMICs). In Kenya, the prevalence is 25 cases per 100,000 women. Approximately 75% cases of cervical cancer are caused by persistent infections of the cervical mucosal epithelium with carcinogenic types of human papillomaviruses (HPVs) mainly 16 and 18.

SARS-CoV-2 belongs to the genus Beta of the Coronaviridae family of enveloped single-stranded, positive-sense ribonucleic acid (RNA) with a genome length of 30,000bp. The virion is composed of various non-structural (RNA dependent RNA polymerase also known as RdRp) and structural proteins such as Spike (S), Nucleocapsid (N), Matrix (M), and Envelope (E) proteins.

According to the World Health Organization (WHO), the human papillomavirus (HPV) affects more than 600 million people worldwide, being the most common sexually transmitted disease (STD). There were over 250,000 deaths due to cervical cancer worldwide and most of them took place in developing countries (WHO). There are more than 80 HPV types and more than 40 infect the genital tract

Background: HIV infection is a major public health problem in sub-Saharan Africa, particularly in Burkina Faso. This study aimed to describe the socio-demographic characteristics of newly person living with HIV initiating antiretroviral treatment at the Adult Day Hospital of Bobo-Dioulasso over a five-year period. Materials and methods: A descriptive cross-sectional study was conducted from 1 January 2016 to 31 December 2020 at the Adult Day Hospital of Bobo-Dioulasso. People newly diagnosed with HIV after confirmatory testing and initiating antiretroviral therapy were included in this study.  

This article is an extension to our recently published article in Asian Journal of Pharmaceutical and Clinical Research, entitled “Β-Sitosterol: Isolation from Muntingia Calabura Linn. Bark Extract, Structural Elucidation, and Molecular Docking Studies as Potential Inhibitor of SARSCoV-2 Mpro (COVID-19)”[1].

At the end of 2019, a novel severe respiratory disease (coronavirus disease 2019, COVID-19) spread to Wuhan, China, it became pandemic in few months, with more than 41 million people infected worldwide as of October 2020. COVID-19 is caused by a novel virus called severe acute respiratory syndrome (SARS) CoV-2 to distinguish it from SARS-CoV that emerged in Guangdong province in China in 2003 and caused the severe clinical condition known as SARS. Like SARS-CoV, SARS- CoV-2 causes a severe inter

In light of the current pandemic from rapid transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) and significant morbidity, there has been inconsistent medical guidance given to the public regarding the wearing of non-medical improvised fabric masks or face coverings to reduce the transmission of COVID-19.

Since the discovery of the hepatitis B virus (HBV) by Blumberg et al., great progress has been made in understanding the pathogenesis of the virus and its role in hepatocellular carcinoma (HCC). It is estimated that hepatitis B is responsible for about 50% of the HCC cases worldwide. Because of geographic variations in HBV incidence, the burden of HBV-related HCC (HBV-HCC) is highest in endemic areas such as Asian-Pacific and sub- Saharan Africa and lowest in the United States and the West.

Severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) is a positive-sense, single-stranded RNA with genome size 26.2, and 31.7 kb coronavirus, covered by an enveloped structure, which is a major source of disaster in the 21st century. A typical CoV contains at least six ORFs in its genome. SARS-CoV-2 is the seventh coronavirus that is known to cause human disease.

Diabetes mellitus is a common metabolic disorder that present with abnormal glucose metabolism. This metabolic disease is prevalent in many countries, worldwide. It is no doubt there might be a chance that diabetes mellitus might co-occur with other medical problems.

Since the declaration of COVID-19 as a pandemic in March 2020, there have been more than 100 million reported cases of COVID-19 worldwide and more than 2.1 million deaths. The purpose of this editorial is to review recent updates regarding COVID-19 disease and SARS-CoV-2 vaccination in cancer patients.

Tenofovir, alias (R)-PMPA, was first divulged as an anti- HIV agent in 1993 [1]. That it would in 2012, become the first antiretroviral agent, approved by the US FDA (Food and Drug Administration) to prevent HIV infection, could have been predicted from the findings of Tsai et al.

 Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant. ProLung™-budesonide may offer anti-inflammatory and protective effects to the lung in COVID-19, yet it’s effect on SARS-CoV-2 replication is unknown.

Hepatitis B virus (HBV) infection is a public health problem, accounting for more than 257 million cases of chronic infection and a major cause of hepatocellular carcinoma (HCC) worldwide. With the vaccination and the advent of nucleos(t)ide analogues (NAs) as antiviral therapy, chronic HBV infection currently accounts for approximately 50% of HCC cases worldwide, a significant decrease from >80% in the 1980’s. The reduced incidence of HBV-related HCC (HBV-HCC) with NAs with lamivudine, entecavir, and tenofovir disoproxil fumarate is well documented.

Cellular components are attractive targets for antiviral therapy because they do not mutate as readily as do viral proteins do [1-3]. The identification of CCR₅ as an HIV-1 coreceptor [4-7], facilitated by the discovery of the antiviral activities of CCR₅ ligand ?-chemokines [8], resulted in the development of new viral entry inhibitors to block CCR₅ binding, including both- small molecules and CCR₅ antibodies

Since isolation in humans in 1983 [1,2], HIV-1 has developed into a global pandemic. But an effective HIV-1 vaccine has not been succeeded despite multiple human vaccine trials performed [3,4]. Challenges to an effective vaccine arise from intrinsic virological and immunological features of HIV-1 [3-8].

Highly-Active Antiretroviral Therapy (HAART) is the recommended treatment and management strategy for HIV infection. Although the existing antiretroviral drugs are indispensably significant in improving the quality and extending the lives of HIV/ AIDS individuals, the drugs still have many limitations including development of resistance, production of toxicity, and their limited availability. 

HIV is no longer only a public health challenge, but also a global threat with a devastating negative impact that has claimed over 35 million lives globally. In 2017, about 36.9 million people live with HIV, and 1.8 million people becoming newly infected with the disease globally [1].

“Women are not dying because of diseases we cannot treat. They are dying because societies have yet to make the decision that their lives are worth saving.”